Thyme Care is a technology company.
Thyme Care has raised $234.0M across 4 funding rounds.
Thyme Care has raised $234.0M in total across 4 funding rounds.
Thyme Care is a Nashville-based technology company founded in 2020 that builds a platform for value-based oncology care management, combining human-guided care teams, purpose-built software, advanced analytics, and AI to deliver personalized cancer navigation and support.[1][3][4] It serves health insurance plans, employers, risk-bearing providers, primary care groups, and oncology practices—reaching over 8 million people nationwide through Medicare, commercial, and employer contracts—by solving fragmented cancer care through proactive interventions that improve outcomes, reduce hospitalizations, and lower total costs while managing more than $5 billion in oncology spend.[1][3][6] The company has achieved profitability, raised $275 million in total funding (including a $97 million round in 2024 from investors like CVS Health Ventures, a16z Bio + Health, Morgan Health, Humana, Texas Oncology, and Memorial Hermann), and earned recognition as a 2024 Fierce 15 company for its innovations in scalable, hybrid care models.[2][3]
Thyme Care was founded in 2020 by CEO and Co-Founder Robin Shah, drawing from expertise in oncology and digital health to address a fragmented cancer care system "not designed for people with cancer."[3][4] The idea emerged from recognizing the need for comprehensive navigation that connects patients with trusted support, timely answers, and coordinated care without endless wait times, prioritizing patients amid misaligned incentives between providers and payers.[4] Key leadership includes President and Chief Medical Officer Bobby Green, MD, an oncologist with 17 years of practice and prior experience at Flatiron Health.[7] Early traction built through partnerships with over 800-1,000 oncologists, innovative value-based payment arrangements, and rapid scaling, culminating in profitability, expanded contracts, and a $97 million funding round that propelled nationwide growth.[1][3]
Thyme Care stands out in oncology care through these key elements:
Thyme Care rides the shift from fee-for-service to value-based care in oncology, a $200+ billion U.S. market strained by fragmentation, high costs, and suboptimal outcomes amid rising cancer prevalence.[1][3] Its timing aligns with payer demands for accountability—via Medicare Advantage, commercial plans, and employer contracts—fueled by market forces like AI advancements, post-pandemic virtual care adoption, and regulatory pushes for efficiency.[2][3] By reducing friction through integrated infrastructure and shared risk, Thyme Care influences the ecosystem as a "care enabler," fostering physician-led models (e.g., akin to AON's network), improving access for underserved patients, and setting standards for tech-human hybrids that could extend to other chronic diseases.[1][5]
Thyme Care's profitability and $5B+ spend management position it for aggressive expansion, leveraging AI to automate more workflows, deepen payer-provider partnerships, and potentially enter adjacent areas like survivorship or multi-cancer protocols.[3] Trends like AI scaling, value-based mandates, and CancerX initiatives will accelerate its growth, evolving its influence from navigation leader to oncology infrastructure standard-bearer. As it transforms a broken system into one prioritizing patients, Thyme Care exemplifies how tech can humanize high-stakes care, delivering better journeys from diagnosis onward.[4][6]
Thyme Care has raised $234.0M in total across 4 funding rounds.
Thyme Care's investors include AlleyCorp, Alumni Ventures, Andreessen Horowitz, CVS Health, Echo Health Ventures, Oak HC/FT, Town Hall Ventures, Waverley Capital, Konstantin von Unger, Vivek Garipalli, Afore Capital, Autotech Ventures.
Thyme Care has raised $234.0M across 4 funding rounds. Most recently, it raised $97.0M Series D in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $97.0M Series D | AlleyCorp, Alumni Ventures, Andreessen Horowitz, CVS Health, Echo Health Ventures, Oak HC/FT, Town Hall Ventures, Waverley Capital, Konstantin von Unger, Vivek Garipalli | |
| Jul 1, 2024 | $55.0M Series C | AlleyCorp, Alumni Ventures, Andreessen Horowitz, CVS Health, Echo Health Ventures, Oak HC/FT, Town Hall Ventures, Waverley Capital, Konstantin von Unger, Vivek Garipalli | |
| Aug 1, 2023 | $60.0M Series B | AlleyCorp, Alumni Ventures, Andreessen Horowitz, CVS Health, Echo Health Ventures, Oak HC/FT, Town Hall Ventures, Waverley Capital, Konstantin von Unger, Vivek Garipalli | |
| Oct 1, 2021 | $22.0M Series A | Afore Capital, AlleyCorp, Alumni Ventures, Andreessen Horowitz, Autotech Ventures, Clocktower Technology Ventures, Convective Capital, CVS Health, Echo Health Ventures, FPV Fund, Human Capital, Humba Ventures, Ribbit Capital, Town Hall Ventures, Konstantin von Unger, Mark Cuban, Tikhon Bernstam, Vivek Garipalli |